Alireza Arzhangzadeh: Antithrombotic Strategies in Coronary Artery Aneurysm, Ectasia, and Slow Flow
Alireza Arzhangzadeh, Reviewer at BMJ, Assistant Professor of Cardiology Department of Cardiology, School of Medicine, Shiraz University of Medical Sciences, shared a post on LinkedIn about a recent article he and his colleges co-authored, published in Clinical Cardiology, adding:
“Proud to have contributed to our recently published systematic review in Clinical Cardiology.
I’m truly grateful to Prof. Hamed Bazrafshan and his team for their trust, guidance, and collaboratio n throughout this project.
Beyond the publication, three practical messages stood out:
- CAE — Treat the thrombotic risk, but individualize the strategy.
In coronary artery ectasia, antithrombotic therapy appears beneficial compared with no therapy, but current evidence does not establish a clear advantage of OAC over DAPT.
- Anticoagulation — Quality matters.
When VKA is used, maintaining an adequate therapeutic range (TTR of 60% or higher) may be as important as choosing anticoagulation itself.
- CAA & CSFP — Avoid a one-size-fits-all approach
Evidence remains limited, making individualized assessment of ischemic vs. bleeding risk central to clinical decision-making.
The practical message for me: the diagnosis may guide us, but the individual patient should ultimately shape the antithrombotic strategy.”
Title: Antithrombotic Therapy in Coronary Artery Aneurysm, Ectasia, and Slow Flow: A Systematic Review
Authors: Nasim Kheirandish, Maliheh Kamali, Alireza Khodadadiyan, Helia Bazroodi, Mohammadhossein Imani, Sahar Ghahramani, Amirhossein Saem, Amirhossein Imani, Haniyeh Alaei, Alireza Abdi-Ardekani, Saideh Jamshidi, Mehdi Bazrafshan, Alireza Arzhangzade, Zahra Hooshanginezhad, Hamed Bazrafshan Drissi
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 26, 2026, 02:15Sherif Mahmoud: Updated Guideline for Antithrombotic-Associated Intracranial Hemorrhage
-
Sep 25, 2026, 20:01Anand Gupta: Timing of DOAC Initiation in Newly Diagnosed Atrial Fibrillation
-
Sep 25, 2026, 19:56Steven Fein: A History of Blood Clots Doesn’t Mean a Healthy Pregnancy Is Out of Reach
-
Sep 25, 2026, 19:54Pedro Perez: “Provoked” VTE May Not Always Mean the Risk Disappears When the Provoking Event Does
-
Sep 25, 2026, 19:53Kemal Karaagac: Calcitriol May Reduce Thrombotic Risk in MASLD
-
Sep 25, 2026, 19:52The SINGLE-AF Trial Anticoagulation for Intermediate Stroke Risk – NEJM
-
Sep 25, 2026, 19:49Shinya Goto: DOAC vs Placebo in Intermediate Stroke Risk of AF in Single Country?
-
Sep 25, 2026, 19:47Bryan Cotton: DOACs Versus Nothing When Stroke Risk Is Not Zero
-
Sep 25, 2026, 19:45Selin Yaman Seval: ITP Is More Than a Low Platelet Count